Are you Dr. Babiker?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4500 San Pablo Rd S
Jacksonville, FL 32224Phone+1 480-301-8000
Summary
- Dr. Hani Babiker, MD is a geriatrician in Jacksonville, Florida. He is currently licensed to practice medicine in Florida, Arizona, and New York. He is affiliated with Mayo Clinic Hospital in Florida.
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2012 - 2015
New York Presbyterian Hospital (Cornell Campus)Fellowship, Geriatric Medicine (Internal Medicine), 2008 - 2009
New York-Presbyterian/QueensResidency, Internal Medicine, 2006 - 2008
Comenius UniversityClass of 2000
Certifications & Licensure
FL State Medical License 2019 - 2026
AZ State Medical License 2009 - 2025
NY State Medical License 2008 - 2014
OH State Medical License 2008 - 2011
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma Start of enrollment: 2018 Apr 15
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) Start of enrollment: 2019 Oct 29
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Start of enrollment: 2020 Jun 18
Publications & Presentations
PubMed
- Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.Paulina Marell, Ioannis Kournoutas, Jennifer Gile, Anina Peersen, Priyanshi Shah
The Oncologist. 2024-12-14 - Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.Reagan M Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A Bucheit
Communications Medicine. 2024-12-02 - 2 citationsDual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma.Naga Malleswara Rao Nakka, Hari Krishnareddy Rachamala, Ramcharan Singh Angom, Nagamalleswara Rao Indla, Shamit Kumar Dutta
Materials Today. Bio. 2024-10-01
Press Mentions
Improving Value in Pancreatic Cancer CareJanuary 4th, 2019
Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic MelanomaNovember 26th, 2018
Immunotherapy—Cancer's New FrontierApril 5th, 2018- Join now to see all
Professional Memberships
- Member
